Regeneron Pharmaceuticals

(NASDAQ: REGN)
Health Care  |  Biotechnology
583.75 2.735 0.47%
Stock Price | July 28, 2021, 12:22 p.m.
0 Followers
Bid: 583.35
Ask: 583.99
Prev. Close: 581.01
52 Week Low: 441.0
52 Week High: 660.0
PE Ratio: 16.51535
Dividend Yield: %

Company Summary

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Read more Read less

Recently Viewed Tickers